Sanofi: vaccine ready by the first half of 2021
French pharmaceutical company Sanofi said it plans to obtain approval for the potential vaccine against Covid-19, which it is developing with British GlaxoSmithKline (GSK), faster than previously anticipated in the first half of next year.
There are several companies running for the vaccine to be used on a large scale: Moderna, the University of Oxford in collaboration with AstraZeneca and an alliance of BioNTech and Pfizer started testing on humans as early as March. Sanofi CEO Paul Hudson said that “there are companies that move faster, but let’s be brutally clear, speed has three negative aspects: they are using existing work, in many cases done for Sars ; it is likely not to be as effective; and there is no guarantee on the supply in large volumes “. The probability of success for Sanofi is “higher than anyone else,” he added.
Sanofi is currently working on two vaccine projects. One uses an adjuvant produced by GSK to potentially enhance its effectiveness. He received financial support from the United States Advanced Biomedical Research and Development Authority (Barda). The other, developed with the American company Translate Bio (in an estimated $ 2.3 billion agreement), is based on a different technology known as mRNA, similar to the Modern approach. Clinical trials of the vaccine developed with GSK, described as a recombinant vaccine, will begin in September. Those for the other towards the end of the year. Sanofi said to have the capacity to produce up to 1 billion doses per year of recombinant vaccine and up to 360 million doses of the mRNA.